Skip to main content

Table 1 Frequency of CD4+CD62Low, CD8+CD62Low, DX5+, CD19+cells in spleen and blood: major subsets

From: Intratumoral delivery of IL-18 naked DNA induces T-cell activation and Th1 response in a mouse hepatic cancer model

Treatment Group

Spleens

Blood

 

CD4+CD62Low (%)

CD8+CD62Low (%)

DX5+ (%)

CD19+ (%)

CD4+CD62Low (%)

CD8+CD62Low (%)

DX5+ (%)

CD19+ (%)

pCEP4

17.75 ± 0.92

0.997 ± 0.05

3.39 ± 1.26

44.51 ± 3.40

17.62 ± 2.15

5.93 ± 0.96

15.45 ± 1.19

28.97 ± 3.52

pIL-18

30.05 ± 1.85a

1.995 ± 0.34

1.73 ± 0.08

41.57 ± 1.09

30.58 ± 4.59a

9.88 ± 0.94

18.4 ± 2.91

36.49 ± 5.95

  1. Spleen and blood samples of CT26 tumor-bearing mice treated with pCEP4 or mIL-18 plasmid DNA were harvested 7 days after gene treatment, and cells analyzed by flow cytometry using the corresponding FITC-, PE-, or PE-Cy5-conjugated antibodies and isotype control. Data are presented as means ± SD of 8 mice/group. a P < 0.04, compared with the pCEP4 control-treated group.